Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinfukang + docetaxel
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Jinfukang + docetaxel is a combination therapy consisting of Jinfukang, a traditional Chinese medicine formula approved in China for non-small cell lung cancer (NSCLC), and docetaxel, a well-established chemotherapeutic agent. Jinfukang is composed of multiple herbal ingredients and has demonstrated anti-tumor effects through inhibition of tumor growth, metastasis, and modulation of cellular immunity. Docetaxel is a taxane-class small molecule that disrupts microtubule function, leading to cell cycle arrest and apoptosis in rapidly dividing cells. The combination aims to enhance anti-cancer efficacy while potentially reducing chemotherapy-related adverse effects. This regimen has been explored primarily for NSCLC but may also be relevant in other cancers where docetaxel is used.
- Other names
- Jinfukang and docetaxelJinfukang plus docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Jinfukang + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jinfukang + docetaxel.